Developer docs
API playgroundTry for free, no card

Search company profiles

Acuitive Technologies

Full company profile

uuid000bvnf

Namestring
Acuitive Technologies
Legal namestring
Acuitive Technologies Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Acuitive Technologies Inc. is a privately held US medical device manufacturer founded in 2014 and headquartered in Allendale, New Jersey, that develops and commercializes orthopedic implants built on a proprietary citrate-based polymer platform called CITREGEN. The CITREGEN technology is a resorbable synthetic biomaterial that releases citrate, calcium, and phosphate during hydrolysis and is metabolized during bone remodeling, designed to overcome the chronic inflammation and inconsistent resorption associated with conventional PLA/PGA-based biodegradable polymers. Acuitive's commercial product portfolio spans five device families: CITREGRAFT (synthetic bioactive bone graft substitute, commercially launched November 2025), CITRELOCK ACL and CITRELOCK Foot & Ankle (soft tissue fixation devices for tendon and ligament reconstruction), CITREFIX (knotless suture anchor), and CITREBRIDGE (investigational 3D-printed rotator cuff interpositional scaffold). The company also operates a research collaboration with Northwestern University (Dr. Guillermo Ameer, CITREGEN co-founder) and has published with the University of Pennsylvania on the CITREBIND concept.

Acuitive monetizes through one-time hardware sales of its orthopedic devices to orthopedic surgeons, sports medicine specialists, hospitals, and ambulatory surgery centers. Pricing is quote-based and not publicly disclosed, and the company runs a hybrid go-to-market combining direct field sales to healthcare providers with an authorized distributor network that recruits via a public inquiry portal on its corporate website. The company markets primarily through its corporate website, LinkedIn presence, press release distribution, and an extensive portfolio of peer-reviewed scientific publications, and has built credibility via FDA 510(k) clearances, a Society for Biomaterials 2022 Technology Innovation and Development Award, and a TERMIS-AM 2022 Innovation/Commercialization Award.

Short descriptiontext

Acuitive Technologies is a private US orthopedic medical device manufacturer founded in 2014 that develops CITREGEN citrate-based polymer implants—including bone graft substitutes, interference screws, and suture anchors—for orthopedic and sports medicine surgeons at US hospitals and surgery centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAllendale, United States
HQ citystring
Allendale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orthopedic medical devices, bone graft substitutes, citrate biomaterial technology, soft tissue fixation, sports medicine implants
Industry3 codes
PRIMARYHLAHAEAF
Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthopedic Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Acuitive Technologies generates revenue through the sale of orthopedic medical devices including bone graft substitutes, soft tissue fixation devices, and suture anchors. The company sells CITREGEN-based products directly to healthcare providers and through distributor networks. Revenue is generated through one-time device purchases for surgical procedures.

acuitivetech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1CITREGEN
Description

Paradigm-changing synthetic biomaterial platform technology using citrate to metabolically guide tissue regeneration.

acuitivetech.com
Core offering1 text field

Acuitive Technologies manufactures CITREGEN-based orthopedic medical devices, including synthetic bioactive bone graft substitutes (CITREGRAFT), knotless suture anchors (CITREFIX), and soft tissue fixation devices (CITRELOCK ACL and CITRELOCK Foot & Ankle), supported by the investigational CITREBRIDGE rotator cuff scaffold. The products serve orthopedic and sports medicine surgeons performing bone repair, soft tissue fixation, and ACL, foot and ankle, and shoulder reconstruction procedures in hospitals and ambulatory surgery centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • In vitro studies demonstrate CITREGRAFT strongly binds key growth factors BMP-2, TGF-β, and PDGF to support consistent regenerative signaling
+2 more records
Product overview1 text field

Acuitive Technologies manufactures CITREGEN-based orthopedic devices for various musculoskeletal applications. The core technology platform is CITREGEN, a citrate-based polymer technology that mimics natural bone chemistry. The product portfolio includes CITREGRAFT (synthetic bone graft substitute), CITREBRIDGE (rotator cuff interpositional scaffold), CITRELOCK ACL and Foot & Ankle (soft tissue fixation devices), and CITREFIX (knotless suture anchor). These devices serve orthopedic applications in knee, foot and ankle, shoulder, elbow, and wrist surgeries, all utilizing the proprietary CITREGEN biomaterial for repair, regeneration, and resorption.

Product and service5 records
1CITREGRAFT
CategoryOrthopedic Bone Graft Substitute
Description

CITREGRAFT is a synthetic, highly porous, bioactive, and resorbable bone graft substitute designed to fill bony voids within the skeletal system. It is pliable and sponge-like, easily morselized, absorbs up to 5 times its weight in body fluid, and comes in various sizes to support new bone growth. CITREGRAFT binds growth factors BMP-2, TGF-β, and PDGF from Bone Marrow Aspirate to support consistent regenerative signaling. It is intended for orthopedic surgeons treating bone voids from trauma, infection, tumor removal, and general bone void filling.

2CITREBRIDGE
CategoryOrthopedic Soft Tissue Repair Scaffold
Description

CITREBRIDGE is a 3D-printed interpositional scaffold placed between soft tissue and bone as an inlay implant, designed to improve both the biological and mechanical aspects of the transitional tissue between the rotator cuff and bone. It targets orthopedic surgeons performing rotator cuff repair. CITREBRIDGE is currently an investigational device and is not available for sale in the United States.

3CITRELOCK ACL
CategoryOrthopedic Soft Tissue Fixation Device
Description

CITRELOCK ACL is a soft tissue fixation device designed as a soft, fluted, self-locking device with a cannula for alignment with surgically prepared sites. Its multi-lead, high-pitch design reduces screw revolutions and prevents tendon laceration or twisting during insertion. CITRELOCK ACL is used for ACL reconstruction procedures by orthopedic sports medicine surgeons.

4CITRELOCK Foot & Ankle
CategoryOrthopedic Soft Tissue Fixation Device
Description

CITRELOCK Foot & Ankle is a soft tissue fixation device that enables secure and efficient tendon fixation in foot and ankle surgical procedures. The multi-lead, high-pitch fluted device can be malleted into a bone tunnel without twisting or lacerating tissue by eliminating screw revolutions, and it is available in multiple sizes for versatile foot and ankle use. It is targeted at orthopedic foot and ankle surgeons.

5CITREFIX
CategoryOrthopedic Suture Anchor
Description

CITREFIX is a barbed, knotless suture anchor designed to attach soft tissue to bone by passing sutures through a PEEK eyelet located at the tip of the device. It provides durable fixation with strong pull-out strength and consistent fixation performance throughout healing. It is intended for orthopedic surgeons performing soft tissue-to-bone anchoring, including rotator cuff and other tendon repair procedures.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Acuitive Technologies collaborated with the University of Pennsylvania to publish research in Advanced Functional Materials detailing the development of a citrate-based, 3D-printed scaffold supporting the CITREBIND concept for controlled orthobiologic delivery. The study demonstrates how the scaffold's engineered anionic surface enables strong protein binding and sustained release for effective bone regeneration with significantly lower BMP-2 doses than clinical practice.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Dr. Guillermo A. Ameer, Daniel Hale Williams Professor of Biomedical Engineering at Northwestern University, is the founder of the CITREGEN technology and serves as a scientific advisor. His research lab pioneered the citrate-based biomaterials that form the foundation of Acuitive's technology platform. The collaboration has produced multiple peer-reviewed publications and enabled the technology transfer from lab to market.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Ireland-based CÚRAM has demonstrated the scientific potential of the CITREGEN bioactive platform technology to expedite tissue healing and mitigate problems associated with currently marketed biodegradable devices for numerous musculoskeletal applications.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Privately held orthopedic sports medicine leader specializing in suture anchors, interference screws, ACL reconstruction, and rotator cuff repair—the exact niches Acuitive targets with CITREFIX, CITRELOCK, and CITREBRIDGE. Most direct product-line competitor.

TypeBroad incumbent
Description

Global orthopedic medical device leader with broad sports medicine, soft tissue repair, and trauma fixation portfolios that directly overlap Acuitive's CITRELOCK and CITREFIX product lines. Comparable as the dominant incumbent whose sales reach Acuitive must compete against.

TypeBroad incumbent
Description

Global orthopedic and sports medicine company with strong soft tissue repair (HEALICOIL suture anchors, BIOSURE interference screws) and orthobiologics portfolios overlapping Acuitive's CITREFIX and CITREGRAFT lines.

TypeDirect peer
Description

Orthopedic sports medicine company selling suture anchors, interference screws, and soft tissue fixation devices directly competing with CITREFIX and CITRELOCK ACL. Mid-size player most comparable in scale and product focus to Acuitive.

TypeBroad incumbent
Description

Major orthopedic device company with sports medicine, ligament reconstruction, and bone graft substitute offerings. Several Acuitive board members came from companies acquired by Zimmer, making it a direct comparable on both product and talent overlap.

TypeDirect peer
Description

Orthobiologics specialist with bone graft substitutes (Osteoamp, Exponent) and regenerative therapies. Closely comparable to Acuitive's CITREGRAFT synthetic bone graft strategy and orthobiologic delivery ambitions.

TypeDirect peer
Description

Orthobiologics and hyaluronic-acid-based regenerative medicine company with bone graft substitute and joint preservation products. Most direct comparable to CITREGRAFT's synthetic bone void filler positioning.

TypeDirect peer
Description

Regenerative medicine company using placental tissue allografts for orthopedic soft tissue repair and wound care. Comparable emerging competitor in the regenerative biomaterials space adjacent to CITREGEN's metabolic biomaterial platform.

9Johnson & Johnson (DePuy Synthes)
TypeBroad incumbent
Description

Orthopedic trauma, sports medicine, and reconstruction franchise through DePuy Synthes and Mitek Sports Medicine. Directly comparable on suture anchors, interference screws, and ligament reconstruction devices.

TypeBroad incumbent
Description

Regenerative medicine and orthopedic company with collagen-based bone graft substitutes and soft tissue repair products (Tissue Technologies). Comparable to Acuitive's regenerative biomaterial platform and bone graft focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acuitive Technologies

Orthopedic Medical Devicesacuitivetech.com

Acuitive Technologies is a private US orthopedic medical device manufacturer founded in 2014 that develops CITREGEN citrate-based polymer implants—including bone graft substitutes, interference screws, and suture anchors—for orthopedic and sports medicine surgeons at US hospitals and surgery centers.

What Acuitive Technologies does

Acuitive Technologies Inc. is a privately held US medical device manufacturer founded in 2014 and headquartered in Allendale, New Jersey, that develops and commercializes orthopedic implants built on a proprietary citrate-based polymer platform called CITREGEN. The CITREGEN technology is a resorbable synthetic biomaterial that releases citrate, calcium, and phosphate during hydrolysis and is metabolized during bone remodeling, designed to overcome the chronic inflammation and inconsistent resorption associated with conventional PLA/PGA-based biodegradable polymers. Acuitive's commercial product portfolio spans five device families: CITREGRAFT (synthetic bioactive bone graft substitute, commercially launched November 2025), CITRELOCK ACL and CITRELOCK Foot & Ankle (soft tissue fixation devices for tendon and ligament reconstruction), CITREFIX (knotless suture anchor), and CITREBRIDGE (investigational 3D-printed rotator cuff interpositional scaffold). The company also operates a research collaboration with Northwestern University (Dr. Guillermo Ameer, CITREGEN co-founder) and has published with the University of Pennsylvania on the CITREBIND concept.

Acuitive monetizes through one-time hardware sales of its orthopedic devices to orthopedic surgeons, sports medicine specialists, hospitals, and ambulatory surgery centers. Pricing is quote-based and not publicly disclosed, and the company runs a hybrid go-to-market combining direct field sales to healthcare providers with an authorized distributor network that recruits via a public inquiry portal on its corporate website. The company markets primarily through its corporate website, LinkedIn presence, press release distribution, and an extensive portfolio of peer-reviewed scientific publications, and has built credibility via FDA 510(k) clearances, a Society for Biomaterials 2022 Technology Innovation and Development Award, and a TERMIS-AM 2022 Innovation/Commercialization Award.

Acuitive Technologies firmographics

Firmographics
Name
Acuitive Technologies
Legal name
Acuitive Technologies Inc.
Website
https://acuitivetech.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Acuitive Technologies is a private US orthopedic medical device manufacturer founded in 2014 that develops CITREGEN citrate-based polymer implants—including bone graft substitutes, interference screws, and suture anchors—for orthopedic and sports medicine surgeons at US hospitals and surgery centers.
Ownership category
akta.pro rank

Acuitive Technologies industry classification

Industry
Product category
Orthopedic Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAF
Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Orthopedic medical devices
  • Bone graft substitutes
  • Citrate biomaterial technology
  • Soft tissue fixation
  • Sports medicine implants

Where Acuitive Technologies is headquartered

Location

Headquarters

HQ city
Allendale
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Acuitive Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

  1. Medical Device Sales: Acuitive Technologies generates revenue through the sale of orthopedic medical devices including bone graft substitutes, soft tissue fixation devices, and suture anchors. The company sells CITREGEN-based products directly to healthcare providers and through distributor networks. Revenue is generated through one-time device purchases for surgical procedures.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Acuitive Technologies product offering

Product offering

Core offering

Acuitive Technologies manufactures CITREGEN-based orthopedic medical devices, including synthetic bioactive bone graft substitutes (CITREGRAFT), knotless suture anchors (CITREFIX), and soft tissue fixation devices (CITRELOCK ACL and CITRELOCK Foot & Ankle), supported by the investigational CITREBRIDGE rotator cuff scaffold. The products serve orthopedic and sports medicine surgeons performing bone repair, soft tissue fixation, and ACL, foot and ankle, and shoulder reconstruction procedures in hospitals and ambulatory surgery centers.

Product overview

Acuitive Technologies manufactures CITREGEN-based orthopedic devices for various musculoskeletal applications. The core technology platform is CITREGEN, a citrate-based polymer technology that mimics natural bone chemistry. The product portfolio includes CITREGRAFT (synthetic bone graft substitute), CITREBRIDGE (rotator cuff interpositional scaffold), CITRELOCK ACL and Foot & Ankle (soft tissue fixation devices), and CITREFIX (knotless suture anchor). These devices serve orthopedic applications in knee, foot and ankle, shoulder, elbow, and wrist surgeries, all utilizing the proprietary CITREGEN biomaterial for repair, regeneration, and resorption.

Differentiator

Problem solved

Functional benefit

Brands

  • CITREGEN: Paradigm-changing synthetic biomaterial platform technology using citrate to metabolically guide tissue regeneration.

Products and services

  • CITREGRAFT CITREGRAFT is a synthetic, highly porous, bioactive, and resorbable bone graft substitute designed to fill bony voids within the skeletal system. It is pliable and sponge-like, easily morselized, absorbs up to 5 times its weight in body fluid, and comes in various sizes to support new bone growth. CITREGRAFT binds growth factors BMP-2, TGF-β, and PDGF from Bone Marrow Aspirate to support consistent regenerative signaling. It is intended for orthopedic surgeons treating bone voids from trauma, infection, tumor removal, and general bone void filling.
  • CITREBRIDGE CITREBRIDGE is a 3D-printed interpositional scaffold placed between soft tissue and bone as an inlay implant, designed to improve both the biological and mechanical aspects of the transitional tissue between the rotator cuff and bone. It targets orthopedic surgeons performing rotator cuff repair. CITREBRIDGE is currently an investigational device and is not available for sale in the United States.
  • CITRELOCK ACL CITRELOCK ACL is a soft tissue fixation device designed as a soft, fluted, self-locking device with a cannula for alignment with surgically prepared sites. Its multi-lead, high-pitch design reduces screw revolutions and prevents tendon laceration or twisting during insertion. CITRELOCK ACL is used for ACL reconstruction procedures by orthopedic sports medicine surgeons.
  • CITRELOCK Foot & Ankle CITRELOCK Foot & Ankle is a soft tissue fixation device that enables secure and efficient tendon fixation in foot and ankle surgical procedures. The multi-lead, high-pitch fluted device can be malleted into a bone tunnel without twisting or lacerating tissue by eliminating screw revolutions, and it is available in multiple sizes for versatile foot and ankle use. It is targeted at orthopedic foot and ankle surgeons.
  • CITREFIX CITREFIX is a barbed, knotless suture anchor designed to attach soft tissue to bone by passing sutures through a PEEK eyelet located at the tip of the device. It provides durable fixation with strong pull-out strength and consistent fixation performance throughout healing. It is intended for orthopedic surgeons performing soft tissue-to-bone anchoring, including rotator cuff and other tendon repair procedures.

Quantifiable outcome

  • In vitro studies demonstrate CITREGRAFT strongly binds key growth factors BMP-2, TGF-β, and PDGF to support consistent regenerative signaling
  • +2 more outcomes

Companies that use Acuitive Technologies

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Acuitive Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Acuitive Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • University of PennsylvaniacoreStrategic or Co-development Partner · 1 June 2025Acuitive Technologies collaborated with the University of Pennsylvania to publish research in Advanced Functional Materials detailing the development of a citrate-based, 3D-printed scaffold supporting the CITREBIND concept for controlled orthobiologic delivery. The study demonstrates how the scaffold's engineered anionic surface enables strong protein binding and sustained release for effective bone regeneration with significantly lower BMP-2 doses than clinical practice.
  • Northwestern University - Dr. Guillermo A. AmeercoreStrategic or Co-development Partner · 1 January 2021Dr. Guillermo A. Ameer, Daniel Hale Williams Professor of Biomedical Engineering at Northwestern University, is the founder of the CITREGEN technology and serves as a scientific advisor. His research lab pioneered the citrate-based biomaterials that form the foundation of Acuitive's technology platform. The collaboration has produced multiple peer-reviewed publications and enabled the technology transfer from lab to market.
  • CÚRAM (Centre for Research in Medical Devices)minorStrategic or Co-development PartnerCollaboration with Ireland-based CÚRAM has demonstrated the scientific potential of the CITREGEN bioactive platform technology to expedite tissue healing and mitigate problems associated with currently marketed biodegradable devices for numerous musculoskeletal applications.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Acuitive Technologies competitors and assessment

Company assessment

Broad incumbents

  • Arthrex: Privately held orthopedic sports medicine leader specializing in suture anchors, interference screws, ACL reconstruction, and rotator cuff repair—the exact niches Acuitive targets with CITREFIX, CITRELOCK, and CITREBRIDGE. Most direct product-line competitor.
  • Stryker: Global orthopedic medical device leader with broad sports medicine, soft tissue repair, and trauma fixation portfolios that directly overlap Acuitive's CITRELOCK and CITREFIX product lines. Comparable as the dominant incumbent whose sales reach Acuitive must compete against.
  • Smith+Nephew: Global orthopedic and sports medicine company with strong soft tissue repair (HEALICOIL suture anchors, BIOSURE interference screws) and orthobiologics portfolios overlapping Acuitive's CITREFIX and CITREGRAFT lines.
  • Zimmer Biomet: Major orthopedic device company with sports medicine, ligament reconstruction, and bone graft substitute offerings. Several Acuitive board members came from companies acquired by Zimmer, making it a direct comparable on both product and talent overlap.
  • Johnson & Johnson (DePuy Synthes): Orthopedic trauma, sports medicine, and reconstruction franchise through DePuy Synthes and Mitek Sports Medicine. Directly comparable on suture anchors, interference screws, and ligament reconstruction devices.
  • Integra LifeSciences: Regenerative medicine and orthopedic company with collagen-based bone graft substitutes and soft tissue repair products (Tissue Technologies). Comparable to Acuitive's regenerative biomaterial platform and bone graft focus.

Direct peers

  • Conmed: Orthopedic sports medicine company selling suture anchors, interference screws, and soft tissue fixation devices directly competing with CITREFIX and CITRELOCK ACL. Mid-size player most comparable in scale and product focus to Acuitive.
  • Bioventus: Orthobiologics specialist with bone graft substitutes (Osteoamp, Exponent) and regenerative therapies. Closely comparable to Acuitive's CITREGRAFT synthetic bone graft strategy and orthobiologic delivery ambitions.
  • Anika Therapeutics: Orthobiologics and hyaluronic-acid-based regenerative medicine company with bone graft substitute and joint preservation products. Most direct comparable to CITREGRAFT's synthetic bone void filler positioning.
  • MiMedx: Regenerative medicine company using placental tissue allografts for orthopedic soft tissue repair and wound care. Comparable emerging competitor in the regenerative biomaterials space adjacent to CITREGEN's metabolic biomaterial platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Acuitive Technologies social profiles

Digital presence

Acuitive Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acuitive Technologies leadership team

Management profile

Number of profiles

Profiles13 records

Acuitive Technologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acuitive Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acuitive Technologies

What does Acuitive Technologies do?

Acuitive Technologies manufactures CITREGEN-based orthopedic medical devices, including synthetic bioactive bone graft substitutes (CITREGRAFT), knotless suture anchors (CITREFIX), and soft tissue fixation devices (CITRELOCK ACL and CITRELOCK Foot & Ankle), supported by the investigational CITREBRIDGE rotator cuff scaffold. The products serve orthopedic and sports medicine surgeons performing bone repair, soft tissue fixation, and ACL, foot and ankle, and shoulder reconstruction procedures in hospitals and ambulatory surgery centers.

Is Acuitive Technologies a public or private company?

Acuitive Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Acuitive Technologies founded?

Acuitive Technologies was founded in 2014. It employs 11 to 50 people.

Where is Acuitive Technologies based?

Acuitive Technologies is headquartered in Allendale, United States, in the North America region.

How does Acuitive Technologies make money?

One revenue line is on record: medical Device Sales.

Who are Acuitive Technologies's main competitors?

Broad incumbents on record are Arthrex, Stryker, Smith+Nephew, Zimmer Biomet, Johnson & Johnson (DePuy Synthes) and Integra LifeSciences. Direct peers are Conmed, Bioventus, Anika Therapeutics and MiMedx.

Does Acuitive Technologies have an API?

No public API is recorded for Acuitive Technologies.

What industry is Acuitive Technologies in?

Acuitive Technologies's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAHAEAF, Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair), with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAcuitive Technologies introduces Citregraft, a unique bone graft substitute designed to bind proteins and enhance regenerationAcuuitive Technologies announced the commercialization and first surgical use of Citregraft, a synthetic bone graft substitute developed using its proprietary citrate-based Citregen polymer technology, with the procedure performed on November 4, 2025. The product is designed to overcome limitations of conventional bone graft substitutes by improving handling, absorbing five times its weight in fluids, and binding proteins to enhance bone regeneration. The company positions Citregraft as an innovative option for surgeons performing bone repair procedures including trauma, infection, tumor removal, and reconstructive surgeries.GlobeNewswireAcuitive Technologies, Inc. Appoints Dr. Wayne Berberian as Chief Medical OfficerAcuitive Technologies appointed Dr. Wayne Berberian as Chief Medical Officer, effective immediately. He will provide clinical direction for regenerative orthopedic products, bringing over 30 years of experience and 100+ publications. The company aims to advance tissue regenerative solutions for musculoskeletal diseases.Northwestern's McCormick School of EngineeringGuillermo Ameer, Center for Advanced Regenerative Engineering: Inventive Activity ReportDaniel Hale Williams Professor Guillermo Ameer received FDA clearance in October 2020 for CITREGENTM, a synthetic resorbable biomaterial used to create orthopedic screw systems for tissue regeneration. Acuitive Technologies, Inc., which holds a sublicense from Ameer's startup VesselTek Biomedical, plans to commercialize the CITRELOCK System in early 2021 alongside an orthopedic distribution partner.GlobeNewswireTwo Industry Veterans Join Acuitive Technologies, Inc. Board of Directors as Independent MembersAcuitive Technologies announced that Vince Forlenza and Gary Fischetti will join its Board of Directors as independent members. Both bring decades of medical technology experience, with Forlenza formerly CEO of B.D. and Fischetti former J&J chairman. The company aims to deliver a market-disruptive bio-regenerative platform for musculoskeletal patients.BioSpaceTwo Industry Veterans Join Acuitive Technologies, Inc. Board of Directors as Independent MembersAcuitive Technologies announced that Vince Forlenza and Gary Fischetti will join its Board of Directors. Both bring decades of medical technology experience, with Forlenza formerly CEO of B.D. and Fischetti former J&J chairman. The company plans to benefit from their insight as it moves into growth.PR NewswireThe 2022 Society for Biomaterials, Technology Innovation and Development Award goes to Dr. Guillermo Ameer and the Acuitive Technologies TeamDr. Guillermo Ameer and Acuitive Technologies received the 2022 Society for Biomaterials award for biomaterials research benefiting patient health. Acuitive's Citregen platform has three FDA clearances, with the Citrelock fixation device launched in September 2021 and additional products planned for Q3 2022.PR NewswireAcuitive Technologies Enters Sports Medicine MarketAcuitive Technologies, Inc. announced it received 510(k) clearance from the U.S. Food and Drug Administration to market the CITRESPLINE and CITRELOCK Ligament Reconstruction Devices, which use the company's patented CITREGEN biomaterial technology. The devices are intended for orthopedic surgeries involving fixation of ligament or tendon tissue repairs in the knee, shoulder, elbow, wrist, hand, ankle, and foot. The company plans to commercialize the products through an orthopedic distribution partner.PR NewswireAcuitive Technologies Granted FDA 510(k) Clearance for CITREFIX™ Knotless Suture AnchorAcuitive Technologies received 510(k) clearance from the U.S. Food and Drug Administration to market the CITREFIX Knotless Suture Anchor System, a bioresorbable synthetic polymer device for orthopedic tissue-to-bone attachment surgeries. The system uses CITREGEN material technology, licensed from Northwestern University and Penn State University following over 15 years of academic research, and is designed for extremities including the shoulder, elbow, wrist, hand, knee, ankle, and foot. The company plans to commercialize the product in mid-2021 through an orthopedic distribution partner.